"... The eventual successful trials in MYC across a significant...

"... The eventual successful trials in MYC across a significant number, if not all, known cancers will make most of the current cancer treatments redundant..."

I see your point, but here’s the thing:

FIRSTLY, as an anticancer drug, RAC’s confirmation that EE-Bisantrene was the isomer used in Sheba-1 and Sheba-2, and that it basically matched the historical results, keeps things grounded for me.

The good part is it validated safety and consistency - EE behaves like the same drug used safely in 1,500+ people.But it’s also a bit underwhelming that this “more potent” version of the drug didn’t clearly outperform the old one in those real-world cases! Maybe it will, when numbers are larger! I hope.

SECONDLY, while the MYC discovery improves how Bisantrene can be used, it doesn’t suddenly make the drug “better” on its own. If the MYC angle was truly the holy grail that makes other treatments obsolete, we would expect at least some kind of outlier signal from those Sheba cases - we didn’t!

So, I would suggest that, for now, Bisantrene (MYC magic or not - isn’t a magic cure-all).But yes, understanding MYC could unlock smarter combos, cleaner sequencing, and better patient selection, etc. That’s where some existing regimens will eventually get pushed aside (if all goes well in the upcoming trials).

And with better selection, something inevitably gets left out! But then comes CPACS!!

So - I think you have a point!